http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Thu, 21 May 2026 17:36:28 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/Corporate+News/Pliant+Therapeutics+to+present+cancer+drug+data+at+ASCO+meeting/26537021.html <p>Pliant Therapeutics Inc. (NASDAQ: PLRX) will present data on its experimental cancer drug PLN-101095 at the 2026 American Society of Clinical Oncology Annual Meeting, scheduled for May 29 to June 2 in Chicago.</p><p>The poster presentation will focus on a cohort expansion of a Phase 1 study evaluating PLN-101095, described as a dual αvβ8/αvβ1 integrin inhibitor, in combination with pembrolizumab for patients with advanced solid tumors that have not responded to immune checkpoint inhibitors. Timothy A. Yap from the University of Texas M.D. Anderson Cancer Center will present the findings on May 30.</p><p>PLN-101095 is currently being tested in FORTIFY, a Phase http://www.streetinsider.com/Corporate+News/Pliant+Therapeutics+to+present+cancer+drug+data+at+ASCO+meeting/26537021.html Thu, 21 May 2026 17:36:28 -0400 PLRX http://www.streetinsider.com/Press+Releases/Pliant+Therapeutics+Announces+Upcoming+Presentation+at+the+2026+American+Society+of+Clinical+Oncology+Annual+Meeting/26536983.html <p align="center"><em>Highlights FORTIFY, the Phase 1b indication expansion trial of PLN-101095 </em><br/><em>enrolling patients with ICI-refractory solid tumors</em></p> <p>SOUTH SAN FRANCISCO, Calif., May 21, 2026 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX) today announced a presentation at the upcoming 2026 American Society of Clinical Oncology (ASCO) Annual Meeting taking place in Chicago, Illinois from May 29 to June 2, 2026.</p> <p><strong>Poster Presentation</strong></p> <p><strong>Title:</strong> <a target="_blank" href="https://www.globenewswire.com/Tracker?data=7n4Ka6859iALwU6Mw1jh49LI_APJ74da7mXg_CS3hUOV1mdACR6SbwDHsc4e5rFvLDCFs2gDyErHwUBxV5nhSc5ryvTj1Cxvnig1auGiicMH1agZz8k_uOpv2FLebMdzPBNcuaciYoZp8W690Q_po0UftwoPpT89V0gbtF10FSpoTo_Z5odFEHukfNyB-nd3GPUWpMQQfO1n6e91K0rkHFUi0JV_UeO_JiowAsWNDEb7L5R8rV1qCv-UrnPcnFoh-6c0hmhN8wxLeyBgRBhwtgjnuiRuQWryz0OF8ZYerTQGjrqLkgaSJeVatqyj9mzMRkmxDLr38fWlm4w2ih_0uVISsfjm88Ic1PGuCodrX4hXRnk55hUelk25g8LyUgT9aWNh1JbAaseKnHdtxszxew==" rel="nofollow" target="_blank">Cohort Expansion of a Phase I Study of PLN-101095, a First-in-Class Dual αvβ8 /αvβ1 Integrin Inhibitor, in Combination with Pembrolizumab in Patients with Advanced Solid Tumors Refractory to Immune http://www.streetinsider.com/Press+Releases/Pliant+Therapeutics+Announces+Upcoming+Presentation+at+the+2026+American+Society+of+Clinical+Oncology+Annual+Meeting/26536983.html Thu, 21 May 2026 17:29:00 -0400 A.33615634 A.50216726 O.07116439 O.21612337 O.38968346 PLRX http://www.streetinsider.com/Press+Releases/Pliant+Therapeutics+Announces+Upcoming+Presentation+at+the+2026+American+Society+of+Clinical+Oncology+Annual+Meeting/26536983.html <p align="center"><em>Highlights FORTIFY, the Phase 1b indication expansion trial of PLN-101095 </em><br/><em>enrolling patients with ICI-refractory solid tumors</em></p> <p>SOUTH SAN FRANCISCO, Calif., May 21, 2026 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX) today announced a presentation at the upcoming 2026 American Society of Clinical Oncology (ASCO) Annual Meeting taking place in Chicago, Illinois from May 29 to June 2, 2026.</p> <p><strong>Poster Presentation</strong></p> <p><strong>Title:</strong> <a target="_blank" href="https://www.globenewswire.com/Tracker?data=7n4Ka6859iALwU6Mw1jh49LI_APJ74da7mXg_CS3hUOV1mdACR6SbwDHsc4e5rFvLDCFs2gDyErHwUBxV5nhSc5ryvTj1Cxvnig1auGiicMH1agZz8k_uOpv2FLebMdzPBNcuaciYoZp8W690Q_po0UftwoPpT89V0gbtF10FSpoTo_Z5odFEHukfNyB-nd3GPUWpMQQfO1n6e91K0rkHFUi0JV_UeO_JiowAsWNDEb7L5R8rV1qCv-UrnPcnFoh-6c0hmhN8wxLeyBgRBhwtgjnuiRuQWryz0OF8ZYerTQGjrqLkgaSJeVatqyj9mzMRkmxDLr38fWlm4w2ih_0uVISsfjm88Ic1PGuCodrX4hXRnk55hUelk25g8LyUgT9aWNh1JbAaseKnHdtxszxew==" rel="nofollow" target="_blank">Cohort Expansion of a Phase I Study of PLN-101095, a First-in-Class Dual αvβ8 /αvβ1 Integrin Inhibitor, in Combination with Pembrolizumab in Patients with Advanced Solid Tumors Refractory to Immune http://www.streetinsider.com/Press+Releases/Pliant+Therapeutics+Announces+Upcoming+Presentation+at+the+2026+American+Society+of+Clinical+Oncology+Annual+Meeting/26536983.html Thu, 21 May 2026 17:29:00 -0400 A.33615634 A.50216726 O.07116439 O.21612337 O.38968346 PLRX http://www.streetinsider.com/Press+Releases/Pliant+Therapeutics+Announces+Upcoming+Presentation+at+the+2026+American+Society+of+Clinical+Oncology+Annual+Meeting/26536983.html <p align="center"><em>Highlights FORTIFY, the Phase 1b indication expansion trial of PLN-101095 </em><br/><em>enrolling patients with ICI-refractory solid tumors</em></p> <p>SOUTH SAN FRANCISCO, Calif., May 21, 2026 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX) today announced a presentation at the upcoming 2026 American Society of Clinical Oncology (ASCO) Annual Meeting taking place in Chicago, Illinois from May 29 to June 2, 2026.</p> <p><strong>Poster Presentation</strong></p> <p><strong>Title:</strong> <a target="_blank" href="https://www.globenewswire.com/Tracker?data=7n4Ka6859iALwU6Mw1jh49LI_APJ74da7mXg_CS3hUOV1mdACR6SbwDHsc4e5rFvLDCFs2gDyErHwUBxV5nhSc5ryvTj1Cxvnig1auGiicMH1agZz8k_uOpv2FLebMdzPBNcuaciYoZp8W690Q_po0UftwoPpT89V0gbtF10FSpoTo_Z5odFEHukfNyB-nd3GPUWpMQQfO1n6e91K0rkHFUi0JV_UeO_JiowAsWNDEb7L5R8rV1qCv-UrnPcnFoh-6c0hmhN8wxLeyBgRBhwtgjnuiRuQWryz0OF8ZYerTQGjrqLkgaSJeVatqyj9mzMRkmxDLr38fWlm4w2ih_0uVISsfjm88Ic1PGuCodrX4hXRnk55hUelk25g8LyUgT9aWNh1JbAaseKnHdtxszxew==" rel="nofollow" target="_blank">Cohort Expansion of a Phase I Study of PLN-101095, a First-in-Class Dual αvβ8 /αvβ1 Integrin Inhibitor, in Combination with Pembrolizumab in Patients with Advanced Solid Tumors Refractory to Immune http://www.streetinsider.com/Press+Releases/Pliant+Therapeutics+Announces+Upcoming+Presentation+at+the+2026+American+Society+of+Clinical+Oncology+Annual+Meeting/26536983.html Thu, 21 May 2026 17:29:00 -0400 A.33615634 A.50216726 O.07116439 O.21612337 O.38968346 PLRX http://www.streetinsider.com/Press+Releases/Pliant+Therapeutics+Announces+Upcoming+Presentation+at+the+2026+American+Society+of+Clinical+Oncology+Annual+Meeting/26536983.html <p align="center"><em>Highlights FORTIFY, the Phase 1b indication expansion trial of PLN-101095 </em><br/><em>enrolling patients with ICI-refractory solid tumors</em></p> <p>SOUTH SAN FRANCISCO, Calif., May 21, 2026 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX) today announced a presentation at the upcoming 2026 American Society of Clinical Oncology (ASCO) Annual Meeting taking place in Chicago, Illinois from May 29 to June 2, 2026.</p> <p><strong>Poster Presentation</strong></p> <p><strong>Title:</strong> <a target="_blank" href="https://www.globenewswire.com/Tracker?data=7n4Ka6859iALwU6Mw1jh49LI_APJ74da7mXg_CS3hUOV1mdACR6SbwDHsc4e5rFvLDCFs2gDyErHwUBxV5nhSc5ryvTj1Cxvnig1auGiicMH1agZz8k_uOpv2FLebMdzPBNcuaciYoZp8W690Q_po0UftwoPpT89V0gbtF10FSpoTo_Z5odFEHukfNyB-nd3GPUWpMQQfO1n6e91K0rkHFUi0JV_UeO_JiowAsWNDEb7L5R8rV1qCv-UrnPcnFoh-6c0hmhN8wxLeyBgRBhwtgjnuiRuQWryz0OF8ZYerTQGjrqLkgaSJeVatqyj9mzMRkmxDLr38fWlm4w2ih_0uVISsfjm88Ic1PGuCodrX4hXRnk55hUelk25g8LyUgT9aWNh1JbAaseKnHdtxszxew==" rel="nofollow" target="_blank">Cohort Expansion of a Phase I Study of PLN-101095, a First-in-Class Dual αvβ8 /αvβ1 Integrin Inhibitor, in Combination with Pembrolizumab in Patients with Advanced Solid Tumors Refractory to Immune http://www.streetinsider.com/Press+Releases/Pliant+Therapeutics+Announces+Upcoming+Presentation+at+the+2026+American+Society+of+Clinical+Oncology+Annual+Meeting/26536983.html Thu, 21 May 2026 17:29:00 -0400 A.33615634 A.50216726 O.07116439 O.21612337 O.38968346 PLRX http://www.streetinsider.com/Press+Releases/Pliant+Therapeutics+Announces+Upcoming+Presentation+at+the+2026+American+Society+of+Clinical+Oncology+Annual+Meeting/26536983.html <p align="center"><em>Highlights FORTIFY, the Phase 1b indication expansion trial of PLN-101095 </em><br/><em>enrolling patients with ICI-refractory solid tumors</em></p> <p>SOUTH SAN FRANCISCO, Calif., May 21, 2026 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX) today announced a presentation at the upcoming 2026 American Society of Clinical Oncology (ASCO) Annual Meeting taking place in Chicago, Illinois from May 29 to June 2, 2026.</p> <p><strong>Poster Presentation</strong></p> <p><strong>Title:</strong> <a target="_blank" href="https://www.globenewswire.com/Tracker?data=7n4Ka6859iALwU6Mw1jh49LI_APJ74da7mXg_CS3hUOV1mdACR6SbwDHsc4e5rFvLDCFs2gDyErHwUBxV5nhSc5ryvTj1Cxvnig1auGiicMH1agZz8k_uOpv2FLebMdzPBNcuaciYoZp8W690Q_po0UftwoPpT89V0gbtF10FSpoTo_Z5odFEHukfNyB-nd3GPUWpMQQfO1n6e91K0rkHFUi0JV_UeO_JiowAsWNDEb7L5R8rV1qCv-UrnPcnFoh-6c0hmhN8wxLeyBgRBhwtgjnuiRuQWryz0OF8ZYerTQGjrqLkgaSJeVatqyj9mzMRkmxDLr38fWlm4w2ih_0uVISsfjm88Ic1PGuCodrX4hXRnk55hUelk25g8LyUgT9aWNh1JbAaseKnHdtxszxew==" rel="nofollow" target="_blank">Cohort Expansion of a Phase I Study of PLN-101095, a First-in-Class Dual αvβ8 /αvβ1 Integrin Inhibitor, in Combination with Pembrolizumab in Patients with Advanced Solid Tumors Refractory to Immune http://www.streetinsider.com/Press+Releases/Pliant+Therapeutics+Announces+Upcoming+Presentation+at+the+2026+American+Society+of+Clinical+Oncology+Annual+Meeting/26536983.html Thu, 21 May 2026 17:29:00 -0400 A.33615634 A.50216726 O.07116439 O.21612337 O.38968346 PLRX http://www.streetinsider.com/Press+Releases/Pliant+Therapeutics+Announces+Upcoming+Presentation+at+the+2026+American+Society+of+Clinical+Oncology+Annual+Meeting/26536983.html <p align="center"><em>Highlights FORTIFY, the Phase 1b indication expansion trial of PLN-101095 </em><br/><em>enrolling patients with ICI-refractory solid tumors</em></p> <p>SOUTH SAN FRANCISCO, Calif., May 21, 2026 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX) today announced a presentation at the upcoming 2026 American Society of Clinical Oncology (ASCO) Annual Meeting taking place in Chicago, Illinois from May 29 to June 2, 2026.</p> <p><strong>Poster Presentation</strong></p> <p><strong>Title:</strong> <a target="_blank" href="https://www.globenewswire.com/Tracker?data=7n4Ka6859iALwU6Mw1jh49LI_APJ74da7mXg_CS3hUOV1mdACR6SbwDHsc4e5rFvLDCFs2gDyErHwUBxV5nhSc5ryvTj1Cxvnig1auGiicMH1agZz8k_uOpv2FLebMdzPBNcuaciYoZp8W690Q_po0UftwoPpT89V0gbtF10FSpoTo_Z5odFEHukfNyB-nd3GPUWpMQQfO1n6e91K0rkHFUi0JV_UeO_JiowAsWNDEb7L5R8rV1qCv-UrnPcnFoh-6c0hmhN8wxLeyBgRBhwtgjnuiRuQWryz0OF8ZYerTQGjrqLkgaSJeVatqyj9mzMRkmxDLr38fWlm4w2ih_0uVISsfjm88Ic1PGuCodrX4hXRnk55hUelk25g8LyUgT9aWNh1JbAaseKnHdtxszxew==" rel="nofollow" target="_blank">Cohort Expansion of a Phase I Study of PLN-101095, a First-in-Class Dual αvβ8 /αvβ1 Integrin Inhibitor, in Combination with Pembrolizumab in Patients with Advanced Solid Tumors Refractory to Immune http://www.streetinsider.com/Press+Releases/Pliant+Therapeutics+Announces+Upcoming+Presentation+at+the+2026+American+Society+of+Clinical+Oncology+Annual+Meeting/26536983.html Thu, 21 May 2026 17:29:00 -0400 A.33615634 A.50216726 O.07116439 O.21612337 O.38968346 PLRX http://www.streetinsider.com/Globe+Newswire/Pliant+Therapeutics+Announces+Upcoming+Presentation+at+the+2026+American+Society+of+Clinical+Oncology+Annual+Meeting/26536983.html <p align="center"><em>Highlights FORTIFY, the Phase 1b indication expansion trial of PLN-101095 </em><br/><em>enrolling patients with ICI-refractory solid tumors</em></p> <p>SOUTH SAN FRANCISCO, Calif., May 21, 2026 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX) today announced a presentation at the upcoming 2026 American Society of Clinical Oncology (ASCO) Annual Meeting taking place in Chicago, Illinois from May 29 to June 2, 2026.</p> <p><strong>Poster Presentation</strong></p> <p><strong>Title:</strong> <a target="_blank" href="https://www.globenewswire.com/Tracker?data=7n4Ka6859iALwU6Mw1jh49LI_APJ74da7mXg_CS3hUOV1mdACR6SbwDHsc4e5rFvLDCFs2gDyErHwUBxV5nhSc5ryvTj1Cxvnig1auGiicMH1agZz8k_uOpv2FLebMdzPBNcuaciYoZp8W690Q_po0UftwoPpT89V0gbtF10FSpoTo_Z5odFEHukfNyB-nd3GPUWpMQQfO1n6e91K0rkHFUi0JV_UeO_JiowAsWNDEb7L5R8rV1qCv-UrnPcnFoh-6c0hmhN8wxLeyBgRBhwtgjnuiRuQWryz0OF8ZYerTQGjrqLkgaSJeVatqyj9mzMRkmxDLr38fWlm4w2ih_0uVISsfjm88Ic1PGuCodrX4hXRnk55hUelk25g8LyUgT9aWNh1JbAaseKnHdtxszxew==" rel="nofollow" target="_blank">Cohort Expansion of a Phase I Study of PLN-101095, a First-in-Class Dual αvβ8 /αvβ1 Integrin Inhibitor, in Combination with Pembrolizumab in Patients with Advanced Solid Tumors Refractory to Immune http://www.streetinsider.com/Globe+Newswire/Pliant+Therapeutics+Announces+Upcoming+Presentation+at+the+2026+American+Society+of+Clinical+Oncology+Annual+Meeting/26536983.html Thu, 21 May 2026 17:29:00 -0400 A.33615634 A.50216726 O.07116439 O.21612337 O.38968346 PLRX http://www.streetinsider.com/Globe+Newswire/Pliant+Therapeutics+Announces+Upcoming+Presentation+at+the+2026+American+Society+of+Clinical+Oncology+Annual+Meeting/26536983.html <p align="center"><em>Highlights FORTIFY, the Phase 1b indication expansion trial of PLN-101095 </em><br/><em>enrolling patients with ICI-refractory solid tumors</em></p> <p>SOUTH SAN FRANCISCO, Calif., May 21, 2026 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX) today announced a presentation at the upcoming 2026 American Society of Clinical Oncology (ASCO) Annual Meeting taking place in Chicago, Illinois from May 29 to June 2, 2026.</p> <p><strong>Poster Presentation</strong></p> <p><strong>Title:</strong> <a target="_blank" href="https://www.globenewswire.com/Tracker?data=7n4Ka6859iALwU6Mw1jh49LI_APJ74da7mXg_CS3hUOV1mdACR6SbwDHsc4e5rFvLDCFs2gDyErHwUBxV5nhSc5ryvTj1Cxvnig1auGiicMH1agZz8k_uOpv2FLebMdzPBNcuaciYoZp8W690Q_po0UftwoPpT89V0gbtF10FSpoTo_Z5odFEHukfNyB-nd3GPUWpMQQfO1n6e91K0rkHFUi0JV_UeO_JiowAsWNDEb7L5R8rV1qCv-UrnPcnFoh-6c0hmhN8wxLeyBgRBhwtgjnuiRuQWryz0OF8ZYerTQGjrqLkgaSJeVatqyj9mzMRkmxDLr38fWlm4w2ih_0uVISsfjm88Ic1PGuCodrX4hXRnk55hUelk25g8LyUgT9aWNh1JbAaseKnHdtxszxew==" rel="nofollow" target="_blank">Cohort Expansion of a Phase I Study of PLN-101095, a First-in-Class Dual αvβ8 /αvβ1 Integrin Inhibitor, in Combination with Pembrolizumab in Patients with Advanced Solid Tumors Refractory to Immune http://www.streetinsider.com/Globe+Newswire/Pliant+Therapeutics+Announces+Upcoming+Presentation+at+the+2026+American+Society+of+Clinical+Oncology+Annual+Meeting/26536983.html Thu, 21 May 2026 17:29:00 -0400 A.33615634 A.50216726 O.07116439 O.21612337 O.38968346 PLRX http://www.streetinsider.com/Globe+Newswire/Pliant+Therapeutics+Announces+Upcoming+Presentation+at+the+2026+American+Society+of+Clinical+Oncology+Annual+Meeting/26536983.html <p align="center"><em>Highlights FORTIFY, the Phase 1b indication expansion trial of PLN-101095 </em><br/><em>enrolling patients with ICI-refractory solid tumors</em></p> <p>SOUTH SAN FRANCISCO, Calif., May 21, 2026 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX) today announced a presentation at the upcoming 2026 American Society of Clinical Oncology (ASCO) Annual Meeting taking place in Chicago, Illinois from May 29 to June 2, 2026.</p> <p><strong>Poster Presentation</strong></p> <p><strong>Title:</strong> <a target="_blank" href="https://www.globenewswire.com/Tracker?data=7n4Ka6859iALwU6Mw1jh49LI_APJ74da7mXg_CS3hUOV1mdACR6SbwDHsc4e5rFvLDCFs2gDyErHwUBxV5nhSc5ryvTj1Cxvnig1auGiicMH1agZz8k_uOpv2FLebMdzPBNcuaciYoZp8W690Q_po0UftwoPpT89V0gbtF10FSpoTo_Z5odFEHukfNyB-nd3GPUWpMQQfO1n6e91K0rkHFUi0JV_UeO_JiowAsWNDEb7L5R8rV1qCv-UrnPcnFoh-6c0hmhN8wxLeyBgRBhwtgjnuiRuQWryz0OF8ZYerTQGjrqLkgaSJeVatqyj9mzMRkmxDLr38fWlm4w2ih_0uVISsfjm88Ic1PGuCodrX4hXRnk55hUelk25g8LyUgT9aWNh1JbAaseKnHdtxszxew==" rel="nofollow" target="_blank">Cohort Expansion of a Phase I Study of PLN-101095, a First-in-Class Dual αvβ8 /αvβ1 Integrin Inhibitor, in Combination with Pembrolizumab in Patients with Advanced Solid Tumors Refractory to Immune http://www.streetinsider.com/Globe+Newswire/Pliant+Therapeutics+Announces+Upcoming+Presentation+at+the+2026+American+Society+of+Clinical+Oncology+Annual+Meeting/26536983.html Thu, 21 May 2026 17:29:00 -0400 A.33615634 A.50216726 O.07116439 O.21612337 O.38968346 PLRX http://www.streetinsider.com/Globe+Newswire/Pliant+Therapeutics+Announces+Upcoming+Presentation+at+the+2026+American+Society+of+Clinical+Oncology+Annual+Meeting/26536983.html <p align="center"><em>Highlights FORTIFY, the Phase 1b indication expansion trial of PLN-101095 </em><br/><em>enrolling patients with ICI-refractory solid tumors</em></p> <p>SOUTH SAN FRANCISCO, Calif., May 21, 2026 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX) today announced a presentation at the upcoming 2026 American Society of Clinical Oncology (ASCO) Annual Meeting taking place in Chicago, Illinois from May 29 to June 2, 2026.</p> <p><strong>Poster Presentation</strong></p> <p><strong>Title:</strong> <a target="_blank" href="https://www.globenewswire.com/Tracker?data=7n4Ka6859iALwU6Mw1jh49LI_APJ74da7mXg_CS3hUOV1mdACR6SbwDHsc4e5rFvLDCFs2gDyErHwUBxV5nhSc5ryvTj1Cxvnig1auGiicMH1agZz8k_uOpv2FLebMdzPBNcuaciYoZp8W690Q_po0UftwoPpT89V0gbtF10FSpoTo_Z5odFEHukfNyB-nd3GPUWpMQQfO1n6e91K0rkHFUi0JV_UeO_JiowAsWNDEb7L5R8rV1qCv-UrnPcnFoh-6c0hmhN8wxLeyBgRBhwtgjnuiRuQWryz0OF8ZYerTQGjrqLkgaSJeVatqyj9mzMRkmxDLr38fWlm4w2ih_0uVISsfjm88Ic1PGuCodrX4hXRnk55hUelk25g8LyUgT9aWNh1JbAaseKnHdtxszxew==" rel="nofollow" target="_blank">Cohort Expansion of a Phase I Study of PLN-101095, a First-in-Class Dual αvβ8 /αvβ1 Integrin Inhibitor, in Combination with Pembrolizumab in Patients with Advanced Solid Tumors Refractory to Immune http://www.streetinsider.com/Globe+Newswire/Pliant+Therapeutics+Announces+Upcoming+Presentation+at+the+2026+American+Society+of+Clinical+Oncology+Annual+Meeting/26536983.html Thu, 21 May 2026 17:29:00 -0400 A.33615634 A.50216726 O.07116439 O.21612337 O.38968346 PLRX http://www.streetinsider.com/Globe+Newswire/Pliant+Therapeutics+Announces+Upcoming+Presentation+at+the+2026+American+Society+of+Clinical+Oncology+Annual+Meeting/26536983.html <p align="center"><em>Highlights FORTIFY, the Phase 1b indication expansion trial of PLN-101095 </em><br/><em>enrolling patients with ICI-refractory solid tumors</em></p> <p>SOUTH SAN FRANCISCO, Calif., May 21, 2026 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX) today announced a presentation at the upcoming 2026 American Society of Clinical Oncology (ASCO) Annual Meeting taking place in Chicago, Illinois from May 29 to June 2, 2026.</p> <p><strong>Poster Presentation</strong></p> <p><strong>Title:</strong> <a target="_blank" href="https://www.globenewswire.com/Tracker?data=7n4Ka6859iALwU6Mw1jh49LI_APJ74da7mXg_CS3hUOV1mdACR6SbwDHsc4e5rFvLDCFs2gDyErHwUBxV5nhSc5ryvTj1Cxvnig1auGiicMH1agZz8k_uOpv2FLebMdzPBNcuaciYoZp8W690Q_po0UftwoPpT89V0gbtF10FSpoTo_Z5odFEHukfNyB-nd3GPUWpMQQfO1n6e91K0rkHFUi0JV_UeO_JiowAsWNDEb7L5R8rV1qCv-UrnPcnFoh-6c0hmhN8wxLeyBgRBhwtgjnuiRuQWryz0OF8ZYerTQGjrqLkgaSJeVatqyj9mzMRkmxDLr38fWlm4w2ih_0uVISsfjm88Ic1PGuCodrX4hXRnk55hUelk25g8LyUgT9aWNh1JbAaseKnHdtxszxew==" rel="nofollow" target="_blank">Cohort Expansion of a Phase I Study of PLN-101095, a First-in-Class Dual αvβ8 /αvβ1 Integrin Inhibitor, in Combination with Pembrolizumab in Patients with Advanced Solid Tumors Refractory to Immune http://www.streetinsider.com/Globe+Newswire/Pliant+Therapeutics+Announces+Upcoming+Presentation+at+the+2026+American+Society+of+Clinical+Oncology+Annual+Meeting/26536983.html Thu, 21 May 2026 17:29:00 -0400 A.33615634 A.50216726 O.07116439 O.21612337 O.38968346 PLRX http://www.streetinsider.com/Globe+Newswire/Pliant+Therapeutics+Announces+Upcoming+Presentation+at+the+2026+American+Society+of+Clinical+Oncology+Annual+Meeting/26536983.html <p align="center"><em>Highlights FORTIFY, the Phase 1b indication expansion trial of PLN-101095 </em><br/><em>enrolling patients with ICI-refractory solid tumors</em></p> <p>SOUTH SAN FRANCISCO, Calif., May 21, 2026 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX) today announced a presentation at the upcoming 2026 American Society of Clinical Oncology (ASCO) Annual Meeting taking place in Chicago, Illinois from May 29 to June 2, 2026.</p> <p><strong>Poster Presentation</strong></p> <p><strong>Title:</strong> <a target="_blank" href="https://www.globenewswire.com/Tracker?data=7n4Ka6859iALwU6Mw1jh49LI_APJ74da7mXg_CS3hUOV1mdACR6SbwDHsc4e5rFvLDCFs2gDyErHwUBxV5nhSc5ryvTj1Cxvnig1auGiicMH1agZz8k_uOpv2FLebMdzPBNcuaciYoZp8W690Q_po0UftwoPpT89V0gbtF10FSpoTo_Z5odFEHukfNyB-nd3GPUWpMQQfO1n6e91K0rkHFUi0JV_UeO_JiowAsWNDEb7L5R8rV1qCv-UrnPcnFoh-6c0hmhN8wxLeyBgRBhwtgjnuiRuQWryz0OF8ZYerTQGjrqLkgaSJeVatqyj9mzMRkmxDLr38fWlm4w2ih_0uVISsfjm88Ic1PGuCodrX4hXRnk55hUelk25g8LyUgT9aWNh1JbAaseKnHdtxszxew==" rel="nofollow" target="_blank">Cohort Expansion of a Phase I Study of PLN-101095, a First-in-Class Dual αvβ8 /αvβ1 Integrin Inhibitor, in Combination with Pembrolizumab in Patients with Advanced Solid Tumors Refractory to Immune http://www.streetinsider.com/Globe+Newswire/Pliant+Therapeutics+Announces+Upcoming+Presentation+at+the+2026+American+Society+of+Clinical+Oncology+Annual+Meeting/26536983.html Thu, 21 May 2026 17:29:00 -0400 A.33615634 A.50216726 O.07116439 O.21612337 O.38968346 PLRX http://www.streetinsider.com/FDA/Atisama+advances+RB042+to+phase+1+multi-dose+study%2C+names+new+board+chair/26501527.html <p>Atisama Therapeutics reported that its experimental drug RB042 has progressed to multiple ascending dose cohorts in a phase 1 clinical trial and appointed Bernard Coulie as chair of its board of directors.</p> <p>The Australian biotechnology company said RB042 has demonstrated safety and tolerability in three of four single ascending dose cohorts completed to date. The first multiple ascending dose cohort has been initiated, with higher-dose cohorts expected to report results in the second half of 2026.</p> <p>RB042 is an inhaled splice-switching oligonucleotide targeting chronic obstructive pulmonary disease. The phase 1 study is evaluating the drug in healthy volunteers and healthy smokers across http://www.streetinsider.com/FDA/Atisama+advances+RB042+to+phase+1+multi-dose+study%2C+names+new+board+chair/26501527.html Fri, 15 May 2026 10:25:15 -0400 O.38968346 PLRX http://www.streetinsider.com/FDA/Atisama+advances+RB042+to+phase+1+multi-dose+study%2C+names+new+board+chair/26501527.html <p>Atisama Therapeutics reported that its experimental drug RB042 has progressed to multiple ascending dose cohorts in a phase 1 clinical trial and appointed Bernard Coulie as chair of its board of directors.</p> <p>The Australian biotechnology company said RB042 has demonstrated safety and tolerability in three of four single ascending dose cohorts completed to date. The first multiple ascending dose cohort has been initiated, with higher-dose cohorts expected to report results in the second half of 2026.</p> <p>RB042 is an inhaled splice-switching oligonucleotide targeting chronic obstructive pulmonary disease. The phase 1 study is evaluating the drug in healthy volunteers and healthy smokers across http://www.streetinsider.com/FDA/Atisama+advances+RB042+to+phase+1+multi-dose+study%2C+names+new+board+chair/26501527.html Fri, 15 May 2026 10:25:15 -0400 O.38968346 PLRX http://www.streetinsider.com/Press+Releases/Atisama+Therapeutics+Advances+RB042+into+Multiple+Ascending+Dose+cohorts+of+Phase+1+Trial+and+Appoints+Bernard+Coulie+as+Chair+of+the+Board/26501523.html <div class="xn-content"> <ul type="disc"><li><i>RB042 Phase 1 trial advances into multiple ascending dose study cohorts, demonstrating safety and tolerability <span id="spanHghlt3fe6">to date</span>.</i></li><li><i><person>Dr. Coulie</person> brings more than 25 years of international biopharma leadership and deep expertise in pulmonary disease to the Atisama Board of Directors.</i></li></ul><p><span class="legendSpanClass"><location value="LU/au..melbou" idsrc="xmltag.org" >MELBOURNE, Australia</location></span>, <span class="legendSpanClass"><chron>May 15, 2026</chron></span> /PRNewswire/ -- Atisama Therapeutics (formerly Rage Bio) ("Atisama" or the "Company"), an Australian clinical-stage biotechnology company developing novel splice-switching oligonucleotide (SSO) therapeutics for chronic inflammatory disease, today reported progress in the Phase 1 study of its lead candidate, RB042, and announced the appointment of Dr. <person>Bernard Coulie</person> as Chair http://www.streetinsider.com/Press+Releases/Atisama+Therapeutics+Advances+RB042+into+Multiple+Ascending+Dose+cohorts+of+Phase+1+Trial+and+Appoints+Bernard+Coulie+as+Chair+of+the+Board/26501523.html Fri, 15 May 2026 10:25:00 -0400 O.38968346 PLRX http://www.streetinsider.com/Press+Releases/Atisama+Therapeutics+Advances+RB042+into+Multiple+Ascending+Dose+cohorts+of+Phase+1+Trial+and+Appoints+Bernard+Coulie+as+Chair+of+the+Board/26501523.html <div class="xn-content"> <ul type="disc"><li><i>RB042 Phase 1 trial advances into multiple ascending dose study cohorts, demonstrating safety and tolerability <span id="spanHghlt3fe6">to date</span>.</i></li><li><i><person>Dr. Coulie</person> brings more than 25 years of international biopharma leadership and deep expertise in pulmonary disease to the Atisama Board of Directors.</i></li></ul><p><span class="legendSpanClass"><location value="LU/au..melbou" idsrc="xmltag.org" >MELBOURNE, Australia</location></span>, <span class="legendSpanClass"><chron>May 15, 2026</chron></span> /PRNewswire/ -- Atisama Therapeutics (formerly Rage Bio) ("Atisama" or the "Company"), an Australian clinical-stage biotechnology company developing novel splice-switching oligonucleotide (SSO) therapeutics for chronic inflammatory disease, today reported progress in the Phase 1 study of its lead candidate, RB042, and announced the appointment of Dr. <person>Bernard Coulie</person> as Chair http://www.streetinsider.com/Press+Releases/Atisama+Therapeutics+Advances+RB042+into+Multiple+Ascending+Dose+cohorts+of+Phase+1+Trial+and+Appoints+Bernard+Coulie+as+Chair+of+the+Board/26501523.html Fri, 15 May 2026 10:25:00 -0400 O.38968346 PLRX http://www.streetinsider.com/PRNewswire/Atisama+Therapeutics+Advances+RB042+into+Multiple+Ascending+Dose+cohorts+of+Phase+1+Trial+and+Appoints+Bernard+Coulie+as+Chair+of+the+Board/26501523.html <div class="xn-content"> <ul type="disc"><li><i>RB042 Phase 1 trial advances into multiple ascending dose study cohorts, demonstrating safety and tolerability <span id="spanHghlt3fe6">to date</span>.</i></li><li><i><person>Dr. Coulie</person> brings more than 25 years of international biopharma leadership and deep expertise in pulmonary disease to the Atisama Board of Directors.</i></li></ul><p><span class="legendSpanClass"><location value="LU/au..melbou" idsrc="xmltag.org" >MELBOURNE, Australia</location></span>, <span class="legendSpanClass"><chron>May 15, 2026</chron></span> /PRNewswire/ -- Atisama Therapeutics (formerly Rage Bio) ("Atisama" or the "Company"), an Australian clinical-stage biotechnology company developing novel splice-switching oligonucleotide (SSO) therapeutics for chronic inflammatory disease, today reported progress in the Phase 1 study of its lead candidate, RB042, and announced the appointment of Dr. <person>Bernard Coulie</person> as Chair http://www.streetinsider.com/PRNewswire/Atisama+Therapeutics+Advances+RB042+into+Multiple+Ascending+Dose+cohorts+of+Phase+1+Trial+and+Appoints+Bernard+Coulie+as+Chair+of+the+Board/26501523.html Fri, 15 May 2026 10:25:00 -0400 O.38968346 PLRX http://www.streetinsider.com/PRNewswire/Atisama+Therapeutics+Advances+RB042+into+Multiple+Ascending+Dose+cohorts+of+Phase+1+Trial+and+Appoints+Bernard+Coulie+as+Chair+of+the+Board/26501523.html <div class="xn-content"> <ul type="disc"><li><i>RB042 Phase 1 trial advances into multiple ascending dose study cohorts, demonstrating safety and tolerability <span id="spanHghlt3fe6">to date</span>.</i></li><li><i><person>Dr. Coulie</person> brings more than 25 years of international biopharma leadership and deep expertise in pulmonary disease to the Atisama Board of Directors.</i></li></ul><p><span class="legendSpanClass"><location value="LU/au..melbou" idsrc="xmltag.org" >MELBOURNE, Australia</location></span>, <span class="legendSpanClass"><chron>May 15, 2026</chron></span> /PRNewswire/ -- Atisama Therapeutics (formerly Rage Bio) ("Atisama" or the "Company"), an Australian clinical-stage biotechnology company developing novel splice-switching oligonucleotide (SSO) therapeutics for chronic inflammatory disease, today reported progress in the Phase 1 study of its lead candidate, RB042, and announced the appointment of Dr. <person>Bernard Coulie</person> as Chair http://www.streetinsider.com/PRNewswire/Atisama+Therapeutics+Advances+RB042+into+Multiple+Ascending+Dose+cohorts+of+Phase+1+Trial+and+Appoints+Bernard+Coulie+as+Chair+of+the+Board/26501523.html Fri, 15 May 2026 10:25:00 -0400 O.38968346 PLRX http://www.streetinsider.com/SEC+Filings/Form++10-Q+++++++PLIANT+THERAPEUTICS%2C++++++For%3A+Mar+31/26469142.html si-local-file:///var/storage/secattach/20260511/26469142.html http://www.streetinsider.com/SEC+Filings/Form++10-Q+++++++PLIANT+THERAPEUTICS%2C++++++For%3A+Mar+31/26469142.html Mon, 11 May 2026 16:11:00 -0400 O.38968346 PLRX http://www.streetinsider.com/SEC+Filings/Form++10-Q+++++++PLIANT+THERAPEUTICS%2C++++++For%3A+Mar+31/26469142.html si-local-file:///var/storage/secattach/20260511/26469142.html http://www.streetinsider.com/SEC+Filings/Form++10-Q+++++++PLIANT+THERAPEUTICS%2C++++++For%3A+Mar+31/26469142.html Mon, 11 May 2026 16:11:00 -0400 O.38968346 PLRX http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++PLIANT+THERAPEUTICS%2C++++++For%3A+May+11/26469027.html si-local-file:///var/storage/secattach/20260511/26469027.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++PLIANT+THERAPEUTICS%2C++++++For%3A+May+11/26469027.html Mon, 11 May 2026 16:08:00 -0400 O.38968346 PLRX http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++PLIANT+THERAPEUTICS%2C++++++For%3A+May+11/26469027.html si-local-file:///var/storage/secattach/20260511/26469027.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++PLIANT+THERAPEUTICS%2C++++++For%3A+May+11/26469027.html Mon, 11 May 2026 16:08:00 -0400 O.38968346 PLRX http://www.streetinsider.com/Press+Releases/Pliant+Therapeutics+Provides+Corporate+Update+and+Reports+First+Quarter+2026+Financial+Results/26468819.html <p align="center"><em>First participant dosed in FORTIFY, a Phase 1b indication expansion trial of PLN-101095</em><br /><br /><em>Oral presentation at AACR 2026 featured updated data from Phase 1 trial of PLN-101095 </em><em>showing deepening of confirmed responses in checkpoint inhibitor-refractory solid tumors</em></p> <p align="center"><em>PLN-101095 spotlighted as novel IO approach as part of AACR's 2026 Highlights Plenary Session</em></p> <p align="left">SOUTH SAN FRANCISCO, Calif., May 11, 2026 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX), a clinical-stage biotechnology company focused on the discovery and development of integrin-based therapeutics, today provided a corporate update and reported first quarter 2026 financial results.</p> http://www.streetinsider.com/Press+Releases/Pliant+Therapeutics+Provides+Corporate+Update+and+Reports+First+Quarter+2026+Financial+Results/26468819.html Mon, 11 May 2026 16:05:00 -0400 PLRX http://www.streetinsider.com/Globe+Newswire/Pliant+Therapeutics+Provides+Corporate+Update+and+Reports+First+Quarter+2026+Financial+Results/26468819.html <p align="center"><em>First participant dosed in FORTIFY, a Phase 1b indication expansion trial of PLN-101095</em><br /><br /><em>Oral presentation at AACR 2026 featured updated data from Phase 1 trial of PLN-101095 </em><em>showing deepening of confirmed responses in checkpoint inhibitor-refractory solid tumors</em></p> <p align="center"><em>PLN-101095 spotlighted as novel IO approach as part of AACR's 2026 Highlights Plenary Session</em></p> <p align="left">SOUTH SAN FRANCISCO, Calif., May 11, 2026 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX), a clinical-stage biotechnology company focused on the discovery and development of integrin-based therapeutics, today provided a corporate update and reported first quarter 2026 financial results.</p> http://www.streetinsider.com/Globe+Newswire/Pliant+Therapeutics+Provides+Corporate+Update+and+Reports+First+Quarter+2026+Financial+Results/26468819.html Mon, 11 May 2026 16:05:00 -0400 PLRX